These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26893168)

  • 1. A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders.
    Ślusarczyk J; Trojan E; Chwastek J; Głombik K; Basta-Kaim A
    Curr Neuropharmacol; 2016; 14(7):705-20. PubMed ID: 26893168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Chemokines in the Pathophysiology of Major Depressive Disorder.
    Milenkovic VM; Stanton EH; Nothdurfter C; Rupprecht R; Wetzel CH
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31075818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines and their receptors in the central nervous system.
    Bajetto A; Bonavia R; Barbero S; Florio T; Schettini G
    Front Neuroendocrinol; 2001 Jul; 22(3):147-84. PubMed ID: 11456467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge.
    O'Sullivan JB; Ryan KM; Harkin A; Connor TJ
    J Neuroimmunol; 2010 Mar; 220(1-2):34-42. PubMed ID: 20061033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular, synaptic, and network effects of chemokines in the central nervous system and their implications to behavior.
    Sowa JE; Tokarski K
    Pharmacol Rep; 2021 Dec; 73(6):1595-1625. PubMed ID: 34498203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Brain-immune interactions and implications in psychiatric disorders].
    Marques AH; Cizza G; Sternberg E
    Braz J Psychiatry; 2007 May; 29 Suppl 1():S27-32. PubMed ID: 17546344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the psychoneuroimmunologic concepts on the etiology of depressive disorders.
    Vidrih B; Karlović D; Pasić MB; Uremović M; Mufić AK; Matosić A
    Acta Clin Croat; 2012 Sep; 51(3):403-9. PubMed ID: 23330406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
    Vignau J; Karila L; Costisella O; Canva V
    Encephale; 2005; 31(3):349-57. PubMed ID: 16142050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation.
    Callewaere C; Banisadr G; Rostène W; Parsadaniantz SM
    J Mol Endocrinol; 2007 Mar; 38(3):355-63. PubMed ID: 17339398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A guide to chemokines and their receptors.
    Hughes CE; Nibbs RJB
    FEBS J; 2018 Aug; 285(16):2944-2971. PubMed ID: 29637711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The progress of chemokines and chemokine receptors in autism spectrum disorders.
    Ye J; Wang H; Cui L; Chu S; Chen N
    Brain Res Bull; 2021 Sep; 174():268-280. PubMed ID: 34077795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell signalling in CNS and immune system in depression and during antidepressant treatment: focus on glial and natural killer cells.
    Kovaru H; Pav M; Kovaru F; Raboch J; Fiserova A
    Neuro Endocrinol Lett; 2009; 30(4):421-8. PubMed ID: 20010506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal immune activation by poly I:C induces expression of cytokines IL-1β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain.
    Arrode-Brusés G; Brusés JL
    J Neuroinflammation; 2012 Apr; 9():83. PubMed ID: 22546005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the CCL2-CCR2 axis in depressive disorders.
    Curzytek K; Leśkiewicz M
    Pharmacol Rep; 2021 Aug; 73(4):1052-1062. PubMed ID: 34031863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-immune interactions and disease susceptibility.
    Marques-Deak A; Cizza G; Sternberg E
    Mol Psychiatry; 2005 Mar; 10(3):239-50. PubMed ID: 15685252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines as biomarkers in depressive disorder: current standing and prospects.
    Lichtblau N; Schmidt FM; Schumann R; Kirkby KC; Himmerich H
    Int Rev Psychiatry; 2013 Oct; 25(5):592-603. PubMed ID: 24151804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal chemokines: versatile messengers in central nervous system cell interaction.
    de Haas AH; van Weering HR; de Jong EK; Boddeke HW; Biber KP
    Mol Neurobiol; 2007 Oct; 36(2):137-51. PubMed ID: 17952658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible contribution of IGF-1 to depressive disorder.
    Szczęsny E; Slusarczyk J; Głombik K; Budziszewska B; Kubera M; Lasoń W; Basta-Kaim A
    Pharmacol Rep; 2013; 65(6):1622-31. PubMed ID: 24553010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases.
    Cartier L; Hartley O; Dubois-Dauphin M; Krause KH
    Brain Res Brain Res Rev; 2005 Feb; 48(1):16-42. PubMed ID: 15708626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokines and chemokine receptors: new actors in neuroendocrine regulations.
    Rostène W; Guyon A; Kular L; Godefroy D; Barbieri F; Bajetto A; Banisadr G; Callewaere C; Conductier G; Rovère C; Mélik-Parsadaniantz S; Florio T
    Front Neuroendocrinol; 2011 Jan; 32(1):10-24. PubMed ID: 20624414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.